Franco-Nevada (NYSE:FNV) Bolsa

Franco-Nevada

Franco-Nevada Corp is a precious-metals-focused royalty and investment company. The company owns a diversified portfolio of precious metals and royalty streams, which is actively managed to generate the bulk of its revenue from gold, silver, and platinum. The company does not operate mines, develop projects, or conduct exploration. Franco-Nevada's short-term financial performance is linked to the price of commodities and the amount of production from its portfolio of producing assets. Its long-term performance is affected by the availability of exploration and development capital. The company holds a portfolio of assets, diversified by commodity, revenue type, and stage of a project, located in the U.S, Canada, and Australia.

Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) has outperformed the market over the past 10 years by 3.21% on an annualized basis producing an average annual return of 14.64%. Currently, Franco-Nevada has a market capitalization of $30.52 billion. 
Buying $1000 In FNV: If an investor had bought $1000 of FNV stock 10 years ago, it would be worth $3,998.49 today based on a price of $158.50 for FNV at the time of writing.
<h3>Franco-Nevada's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752528618_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In Franco-Nevada 10 Years Ago Would Be Worth This Much Today

Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) has outperformed the market over the past 10 years by 1.91% on an annualized basis producing an average annual return of 13.38%. Currently, Franco-Nevada has a market capitalization of $30.66 billion. 
Buying $100 In FNV: If an investor had bought $100 of FNV stock 10 years ago, it would be worth $349.63 today based on a price of $159.20 for FNV at the time of writing.
<h3>Franco-Nevada's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752098414_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the <a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/46157351/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-71">EXCLUSIVE: June&#8217;s 20 Most-Searched Tickers On Benzinga Pro — Where Do CoreWeave, Nvidia, Apple Stock Rank?</a>
Here&#8217;s a look at the Benzinga Stock Whisper Index for the week ending July 4:
US Foods Holding Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>): The food service distributor saw increased interest from readers during the shortened holiday week. JPMorgan maintained a Neutral rating on the stock while <a href="https://www.benzinga.com/quote/USFD/analyst-ratings">raising the price target </a>from $82 to $85. US Foods shares trade near all time highs with momentum coming from the earnings report <a href="https://www.benzinga.com/25/05/45297979/whats-going-on-with-us-foods-stock-on-thursday">back in May.</a> The company missed Street estimates for earnings per share and revenue, while reporting a 4.5% year-over-year sales increase and increased gross profits and total case volume. The company's net income was up 40% year-over-year in the first quarter. After a strong quarterly report and a June defense agency contract award win, the company could be one to watch.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703"><img loading="lazy" decoding="async" width="999" height="497" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165727/Screenshot-486.png" alt="" class="wp-image-972632" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165727/Screenshot-486.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165727/Screenshot-486-300x149.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165727/Screenshot-486-768x382.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Franco-Nevada Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>): Interest has been rising in gold and precious metals stocks in recent weeks. This week's Stock Whisper Index sees a precious metals company make it, but one of a different nature. Unlike past stocks that mine the metals that have made the list, Franco-Nevada is a gold-focused royalty and streaming company. The company does not operate mines or conduct exploration, instead owning a portfolio of royalties and streams. Franco-Nevada has a history of increasing its dividend and could be viewed as a safer bet in the sector than some of the other companies. UBS maintained a Buy rating and <a href="https://www.benzinga.com/quote/FNV/analyst-ratings">raised the price target</a> from $205 to $210.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703"><img loading="lazy" decoding="async" width="997" height="496" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165742/Screenshot-487.png" alt="" class="wp-image-972633" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165742/Screenshot-487.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165742/Screenshot-487-300x149.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165742/Screenshot-487-768x382.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
Johnson Controls International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>): The commercial HVAC and building management company saw strong interest from readers during the week, which comes with analysts increasing their price target on the stock in recent months. Johnson Controls shares recently hit new all time highs with the stock up 35% year-to-date in 2025. Investors could be getting ready for upcoming third-quarter financial results, which are expected in late July. The company has beaten analyst estimates for earnings per share and revenue in two straight quarters. The strong recent earnings momentum along with an increased share buyback plan could see shares continue to take out new highs.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703"><img loading="lazy" decoding="async" width="995" height="505" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165757/Screenshot-488.png" alt="" class="wp-image-972634" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165757/Screenshot-488.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165757/Screenshot-488-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165757/Screenshot-488-768x390.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Northrop Grumman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>): One of the largest defense contractors, Northrop Grumman saw increased interest from readers during the week with tensions in the Middle East<a href="https://www.benzinga.com/markets/equities/25/06/46045651/northrop-grumman-jumps-5-overnight-as-b-2-bombers-return-to-missouri-after-36-hour-iran-strike-trump-says-job-well-done"> remaining heightened.</a> The company manufactures the B2 bomber and is involved in several other top defense weapons used. Investors are likely anticipating the company's second-quarter financial results later this month with analysts forecasting earnings per share to grow to $6.70 and revenue to decline to $10.11 billion. The company has beaten analyst estimates for earnings per share in nine of the last 10 quarters and for revenue in seven of the last 10 quarters. Northrop Grumman could be a winner if tension escalates in the Middle East and potentially thanks to increased defense spending by the US and other nations.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703"><img loading="lazy" decoding="async" width="999" height="503" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165811/Screenshot-489.png" alt="" class="wp-image-972635" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165811/Screenshot-489.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165811/Screenshot-489-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165811/Screenshot-489-768x387.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>): The biotech best known for its work on HIV and Hepatitis drugs recently<a href="https://www.benzinga.com/news/fda/25/06/46023093/fda-approves-gileads-game-changing-twice-yearly-shot-to-prevent-hiv-transmission-critics-slam-28k-price-tag"> received FDA approval</a> for Yeztugo, the first and only twice-yearly option in the US for pre-exposure prophylaxis to reduce the risk of HIV in adults. While the company received approval there are questions over how much the drug will be priced at with Gilead working with insurers to increase coverage options. High pricing of the drug could cause pushback against the company, while also helping boost revenue and earnings. Gilead is set to report quarterly financial results in August and could provide an update on the drug. The company has beaten analyst estimates in five straight quarters and beaten analyst revenue estimates in nine of the last 10 quarters.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703"><img loading="lazy" decoding="async" width="1001" height="494" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165827/Screenshot-490.png" alt="" class="wp-image-972636" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165827/Screenshot-490.png 1001w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165827/Screenshot-490-300x148.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165827/Screenshot-490-768x379.png 768w" sizes="(max-width: 1001px) 100vw, 1001px" /></a></figure>
Stay tuned for next week's report, and follow Benzinga Pro for all the latest headlines and <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45827517/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-68" target="_blank" rel="noreferrer noopener">June 6</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45938888/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-69" target="_blank" rel="noreferrer noopener">June 13</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/46043300/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-70" target="_blank" rel="noreferrer noopener">June 20</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/46157351/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-71">June 27</a></li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46236448/exclusive-2025s-first-half-most-searched-tickers-on-benzinga-pro-where-do-nvidia-tesla-apple-stock-rank">EXCLUSIVE: 2025&#8217;s First Half Most-Searched Tickers On Benzinga Pro — Where Do Nvidia, Tesla, Apple Stock Rank?</a></li>
</ul>

Long Ideas

Exclusives

GILD

USFD

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

UBS analyst Daniel Major maintains Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) with a Buy and raises the price target from $205 to $210.

Price Target

Analyst Ratings

UBS Maintains Buy on Franco-Nevada, Raises Price Target to $210

WIIM

CGAU

PAAS

RGLD

SSRM

Shares of precious metals are trading lower amid Israel-Iran ceasefire efforts.

Franco-Nevada Corporation ("Franco-Nevada") (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FNV#TSX">FNV</a>) (NYSE:&nbsp;FNV) provides an update regarding its arbitration proceeding related to the Cobre Panama mine. Following engagement with the Government of Panama's legal counsel, Franco-Nevada has agreed today to suspend its arbitration proceeding. Franco-Nevada had previously filed a request for arbitration under the Canada-Panama Free Trade Agreement to the International Centre for Settlement of Investment Disputes on June 27, 2024.

TSX:FNV

Franco-Nevada Suspends Arbitration Against Panama Over Cobre Panama Mine Following Government Engagement

USAU

Shares of precious metals stocks are trading lower as gold prices fall after reports allege that Iran wants to de-escalate hostilities with Israel. Investor optimism about potential resolutions to regional tensions may drive a rotation out of safe-haven assets.

Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) has outperformed the market over the past 10 years by 1.92% on an annualized basis producing an average annual return of 13.03%. Currently, Franco-Nevada has a market capitalization of $31.90 billion. 
Buying $1000 In FNV: If an investor had bought $1000 of FNV stock 10 years ago, it would be worth $3,409.18 today based on a price of $165.65 for FNV at the time of writing.
<h3>Franco-Nevada's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749650418_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Franco-Nevada 10 Years Ago Would Be Worth Today

Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) has outperformed the market over the past 10 years by 2.79% on an annualized basis producing an average annual return of 13.87%. Currently, Franco-Nevada has a market capitalization of $34.09 billion. 
Buying $100 In FNV: If an investor had bought $100 of FNV stock 10 years ago, it would be worth $356.92 today based on a price of $177.00 for FNV at the time of writing.
<h3>Franco-Nevada's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749080713_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Franco-Nevada 10 Years Ago Would Be Worth Today

Shares of precious metals stocks are trading higher as gold and silver prices rise amid dollar weakness.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham raised Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) price target from $115 to $125. Needham analyst Mike Cikos maintained a Buy rating. Okta shares closed at $125.50 on Tuesday. See how other<a href="https://www.benzinga.com/quote/OKTA/analyst-ratings"> analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. raised the price target for Franco-Nevada Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) from $180 to $195. HC Wainwright &amp; Co. analyst Heiko Ihle maintained a Buy rating. Franco-Nevada shares closed at $168.24 on Tuesday. <a href="https://www.benzinga.com/quote/FNV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies cut Rocket Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) price target from $29 to $2.5. Jefferies analyst Andrew Tsai downgraded the stock from Buy to Hold. Rocket Pharmaceuticals shares closed at $2.33 on Tuesday. <a href="https://www.benzinga.com/quote/RCKT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo increased the price target for Barings BDC, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBDC#NYSE">BBDC</a>) from $8.5 to $9.5. Wells Fargo analyst Finian O&#8217;Shea upgraded the stock from Equal-Weight to Overweight. Barings BDC shares closed at $9.24 on Tuesday. <a href="https://www.benzinga.com/quote/bbdc/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo cut the price target for Runway Growth Finance Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RWAY#NASDAQ">RWAY</a>) from $10 to $9.5. Wells Fargo analyst Finian O&#8217;Shea downgraded the stock from Overweight to Equal-Weight. Runway Growth Finance shares closed at $9.83 on Tuesday. See how <a href="https://www.benzinga.com/quote/RWAY/analyst-ratings">other analysts view this stock</a>.</li>
<li>D. Boral Capital cut CollPlant Biotechnologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) price target from $14 to $12. D. Boral Capital analyst Jason Kolbert maintained a Buy rating. CollPlant Biotechnologies shares settled at $1.93 on Tuesday. <a href="https://www.benzinga.com/quote/CLGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity increased Bridger Aerospace Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) price target from $5 to $5.25. Canaccord Genuity analyst Austin Moeller maintained a Buy rating. Bridger Aerospace shares closed at $1.37 on Tuesday. <a href="https://www.benzinga.com/quote/BAER/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity cut Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) price target from $400 to $350. Canaccord Genuity analyst David Hynes maintained a Buy rating. Salesforce shares closed at $277.19 on Tuesday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies cut the price target for Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) from $7 to $6. Jefferies analyst Julien Dumoulin-Smith maintained a Hold rating. Sunrun shares settled at $7.19 on Tuesday. <a href="https://www.benzinga.com/quote/RUN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo raised The Williams Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) price target from $64 to $67. Wells Fargo analyst Praneeth Satish maintained an Overweight rating. Williams Companies shares closed at $60.10 on Tuesday. <a href="https://www.benzinga.com/quote/WMB/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying OKTA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28084823/image-360-1024x585.png" alt="" class="wp-image-929866" style="width:606px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28084823/image-360-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28084823/image-360-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28084823/image-360-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28084823/image-360.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45616471/jim-cramer-says-rocket-is-a-very-fine-company-recommends-buying-this-health-care-stock">Jim Cramer Says Rocket Is A &#8216;Very Fine&#8217; Company, Recommends Buying This Health Care Stock</a> </li>
</ul>
Photo via Shutterstock

Markets

BAER

BBDC

CLGN

OKTA

PRTA

PTCT

RCKT

RWAY

Williams Companies To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Wednesday

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) with a Buy and raises the price target from $180 to $195.

HC Wainwright & Co. Maintains Buy on Franco-Nevada, Raises Price Target to $195

Franco-Nevada Inks $1.05B Deal To Acquire 7.5% Gross Margin Royalty On Ontario's Côté Gold Mine From Private Seller

Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) has outperformed the market over the past 10 years by 1.45% on an annualized basis producing an average annual return of 12.35%. Currently, Franco-Nevada has a market capitalization of $31.69 billion. 
Buying $1000 In FNV: If an investor had bought $1000 of FNV stock 10 years ago, it would be worth $3,203.43 today based on a price of $164.56 for FNV at the time of writing.
<h3>Franco-Nevada's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747773019_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Scotiabank analyst Tanya Jakusconek maintains Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) with a Sector Perform and raises the price target from $165 to $169.

Scotiabank Maintains Sector Perform on Franco-Nevada, Raises Price Target to $169

GOLD

Shares of precious metals stocks are trading lower as gold and silver drop after the US and China agreed to a temporary reduction in most tariffs on each other's goods. This could be driving a rotation out of safe-haven assets.

Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) reported quarterly earnings of $1.07 per share which beat the analyst consensus estimate of $1.00 by 7 percent. This is a 40.79 percent increase over earnings of $0.76 per share from the same period last year. The company reported quarterly sales of $368.40 million which beat the analyst consensus estimate of $311.02 million by 18.45 percent. This is a 43.46 percent increase over sales of $256.80 million the same period last year.

Earnings

Earnings Beats

Franco-Nevada Q1 Adj. EPS $1.07 Beats $1.00 Estimate, Revenue $368.40M Beat $311.02M Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) has outperformed the market over the past 15 years by 1.96% on an annualized basis producing an average annual return of 12.81%. Currently, Franco-Nevada has a market capitalization of $32.88 billion. 
Buying $100 In FNV: If an investor had bought $100 of FNV stock 15 years ago, it would be worth $595.80 today based on a price of $170.75 for FNV at the time of writing.
<h3>Franco-Nevada's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745879411_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Franco-Nevada 15 Years Ago Would Be Worth Today

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/04/21/final-trades-take-two-interactive-franco-nevada-amgen-and-the-10-year-treasury.html">Halftime Report Final Trades</a>,&#8221; Brian Belski of BMO Capital Markets named Take-Two Interactive Software, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) as <a href="https://www.benzinga.com/quote/TTWO/earnings">his final trade</a>.
On the earnings front, Take-Two Interactive Software will report financial results for its fourth quarter, after the closing bell on Thursday, May 15. Analysts expect the company to report a quarterly loss at 6 cents per share on revenue of $1.55 billion.
Amy Raskin, CIO at Chevy Chase Trust picked Franco-Nevada Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) as her final trade.
Supporting her choice, Scotiabank analyst Tanya Jakusconek raised the price target on the stock from $150 to $165 on April 14.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Stephen L. Weiss of Short Hills Capital Partners selected the U.S. 10-year Treasury.
Joseph M. Terranova of Virtus Investment Partners named Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) as his final trade.
Supporting his view, UBS analyst Colin Bristow maintained Amgen with a Neutral rating on April 14 and raised the price target from $315 to $319.
Price Action:
<ul>
<li>Take-Two Interactive shares fell 3.6% to close at $205.16 on Monday.</li>
<li>Franco-Nevada gained 1.2% to close at $173.18 during Monday's session.</li>
<li>Amgen shares fell 1.3% to close at $273.68 on Monday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44895495/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo: Shutterstock

Media

AMGN

TTWO

Amgen, Franco-Nevada, Take-Two Interactive And More: CNBC's 'Final Trades'

Press Releases

Franco-Nevada Provides Details on Upcoming Investor Day

Franco-Nevada Files Year-End Disclosure Documents

Franco-Nevada to Release First Quarter 2025 Results

Franco-Nevada Launches 2025 Asset Handbook and Sustainability Report

Franco-Nevada Reports Record Q1 2025 Results

Franco-Nevada Announces Election of Directors

Franco-Nevada Announces Acquisition of Cash Flowing Royalty on Côté Gold Mine in Ontario

Comments

Franco-Nevada

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL